ABSTRACT
Introduction
Methods
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerReferences
- Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma.J Clin Oncol. 2007; 25: 4952-4960https://doi.org/10.1200/JCO.2006.08.0499
- Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.New England Journal of Medicine. 2016; 375: 1438-1447https://doi.org/10.1056/NEJMOA1600249/SUPPL_FILE/NEJMOA1600249_DISCLOSURES.PDF
- Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study.Journal of Clinical Oncology. 2014; 32: 2142https://doi.org/10.1200/JCO.2013.53.1608
- The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.Breast Cancer Res Treat. 2016; 158: 361-371https://doi.org/10.1007/S10549-016-3878-9
- Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.Cancer Research. 2009; 69 (62-62)https://doi.org/10.1158/0008-5472.SABCS-09-62
- Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer trial.Journal of Clinical Oncology. 2009; 27: 5685-5692https://doi.org/10.1200/JCO.2008.21.4577
- Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial.Journal of Clinical Oncology. 2009; 27: 6129-6134https://doi.org/10.1200/JCO.2009.23.0946
- Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; Tla,bN0M0): A review of the literature.Journal of Clinical Oncology. 2006; 24: 2113-2122https://doi.org/10.1200/JCO.2005.02.8035
- Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.J Clin Oncol. 2009; 27: 5693-5699https://doi.org/10.1200/JCO.2009.22.0962
- A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: Who might be possible candidates for adjuvant treatment?.Breast Cancer Research and Treatment. 2010; 119: 653-661https://doi.org/10.1007/S10549-009-0665-X/TABLES/3
- Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer.Cancer Treat Res Commun. 2018; 16: 38-44https://doi.org/10.1016/J.CTARC.2018.06.001
- Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?.Ann Oncol. 2011; 22: 2387-2393https://doi.org/10.1093/ANNONC/MDQ786
- Using the National Cancer Database for Outcomes Research: A Review.JAMA Oncol. 2017; 3: 1722-1728https://doi.org/10.1001/jamaoncol.2016.6905
- Incident Cases Captured in the National Cancer Database Compared with Those in U.S. Population Based Central Cancer Registries in 2012–2014.Annals of Surgical Oncology. 2019; 26: 1604-1612https://doi.org/10.1245/s10434-019-07213-1
- Neoadjuvant Therapy for HER2-positive Breast Cancer.Rev Recent Clin Trials. 2017; 12: 81-92https://doi.org/10.2174/1574887112666170202165049
Petruolo O, Sevilimedu V, Montagna G, Le, Bs T, Morrow M, Barrio A V. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?Annals of Surgical Oncology. 28. doi:10.1245/s10434-020-08593-5
- Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.J Clin Oncol. 2012; 30: 1796-1804https://doi.org/10.1200/JCO.2011.38.8595
- Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.Breast Cancer Res Treat. 2021; 187: 903-913https://doi.org/10.1007/S10549-021-06137-3
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.New England Journal of Medicine. 2019; 380: 617-628https://doi.org/10.1056/NEJMOA1814017/SUPPL_FILE/NEJMOA1814017_DATA-SHARING.PDF
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.The Lancet Oncology. 2012; 13: 25-32https://doi.org/10.1016/S1470-2045(11)70336-9
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).Ann Oncol. 2013; 24: 2278-2284https://doi.org/10.1093/ANNONC/MDT182
- Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors.Annals of Surgical Oncology. 2015; 22: 3369-3375https://doi.org/10.1245/S10434-015-4718-6/TABLES/2
- Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).Breast Cancer Research and Treatment. 2021; 187: 177-185https://doi.org/10.1007/S10549-020-06041-2/TABLES/2
Abraham J, Aft R, Agnese D, et al. NCCN Guidelines Version 2.2022 Breast Cancer. Published 202AD. Accessed February 24, 2022. https://www.nccn.
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer.New England Journal of Medicine. 2005; 353: 1659-1672https://doi.org/10.1056/NEJMOA052306/SUPPL_FILE/NEJM_PICCART_1659SA1-2.PDF
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.New England Journal of Medicine. 2017; 377: 122-131https://doi.org/10.1056/NEJMOA1703643/SUPPL_FILE/NEJMOA1703643_DISCLOSURES.PDF
- Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer.Journal of Clinical Oncology. 2019; 37: 1868-1875https://doi.org/10.1200/JCO.19.00066
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.Journal of Clinical Oncology. 2021; 39: 2375-2385https://doi.org/10.1200/JCO.20.03398
- The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?.Clinical Breast Cancer. 2020; 20: 503-510https://doi.org/10.1016/J.CLBC.2020.05.012
- A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysis.Cancer. 2022; 128: 2433-2440https://doi.org/10.1002/CNCR.34200
- A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.Breast Cancer Research and Treatment. 2019; 178: 647-656https://doi.org/10.1007/S10549-019-05413-7
- Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.Scientific Reports 2022 12:1. 2022; 12: 1-8https://doi.org/10.1038/s41598-022-05209-8
- A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive.HER2-positive Breast Cancer - Full Text View - ClinicalTrials.gov. 2022; (Accessed July 6)
ATEMPT 2.0: Adjuvant T-DM1 vs TH - Full Text View - ClinicalTrials.gov. Accessed July 6, 2022. https://clinicaltrials.gov/ct2/show/NCT04893109
Article Info
Publication History
Publication stage
In Press Journal Pre-ProofFootnotes
Accepted for presentation in poster format at the 23rd Annual Meeting of the American Society of Breast Surgeons, April 2022.